{
  "docId": "019de076-5923-773b-8485-b914b8e85d5b",
  "docSlug": "aa767e092bc23262b7b522a6b0c001e5",
  "documentTitle": "MindMed | Results Presentation Deck | 20 slides",
  "authorId": "mindmed",
  "authorName": "MindMed",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 20,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "problem_statement",
  "function": "diagnose_problem",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses a problem-solution framing, contrasting the large GAD patient population with the failure rates of existing therapies.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-5923-773b-8485-b914b8e85d5b/7",
  "deckHref": "/decks/019de076-5923-773b-8485-b914b8e85d5b",
  "deckJsonHref": "/decks/019de076-5923-773b-8485-b914b8e85d5b.json",
  "deckAnchorHref": "/decks/019de076-5923-773b-8485-b914b8e85d5b#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.64,
        "y": 0.00145
      },
      "kind": "callout",
      "text": "Potential Best-in-Class Therapy with Novel MOA",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "908b2461-df95-4795-8d1c-cf66228bd2bb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.05,
        "y": 0.0062
      },
      "kind": "list",
      "text": "Significant Need for New Treatment Options: SSRI/SNRIs: 50% failure rate; Benzodiazepines: addiction/tolerance; Buspirone: poor efficacy; Antipsychotics: short/long-term risks",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "35be9258-8774-4296-8f12-d3b5388cbe35",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.55,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "paragraph",
      "text": "Opportunity in Generalized Anxiety Disorder (GAD): GAD is the 2nd most common mental disorder among adults 18 to 65 years old, yet choices are limited beyond SSRI/SNRIs. Symptoms are debilitating and side effects / lack of efficacy often lead to frequent treatment change until patient is considered treatment resistant.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6eafbcbd-0053-4002-8df0-485de7c5b7e4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.53,
        "x": 0.16,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "1. Mental and Substance Use Disorders Prevalence Study (MDPSU)... 4. Garakani A, et al., (2020) Pharmacotherapy of Anxiety Disorders...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b0b8b816-7990-4377-b19e-405886ea8da6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.0040999999999999995
      },
      "kind": "table",
      "text": "Large Market Opportunity: ~20 million US adults with GAD, 77% have moderate to severe GAD; 13 million receive treatment; 6.5 million do not respond to first-line treatment (SSRI)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62d106ee-8859-46af-bf30-b92e29d65a66",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.94,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "MM-120 | Addressing a Large Unmet Need for Better Anxiety Treatments",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a5b7ba32-e6de-4678-90b2-3f78fe548721",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem-Agitate-Solve (PAS)",
      "slug": "problem-agitate-solve-pas",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "8b6b919f-0c9d-49df-8d54-0617f2fa2698",
      "evidence": "Significant Need for New Treatment Options: SSRI/SNRIs: 50% failure rate; Benzodiazepines: addiction/tolerance; Buspirone: poor efficacy; Antipsychotics: short/long-term risks",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "before-after-framing",
      "slug": null,
      "matchId": "14c50ff3-98af-4fca-b316-11beecc61098",
      "evidence": "Contrasts current unmet needs with the proposed solution (MM-120).",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 7,
      "from": 5,
      "beatId": "b8862ada-2c78-449a-b64d-a21f02947639",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem (Identify pain)",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "Slides 5, 7 highlight the urgent need for better treatments and specific unmet needs.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 7,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "a4571dce-1b11-400c-9e96-0b8287027da2",
      "evidence": "The problem statement slides highlight the urgent need for better treatments.",
      "position": 0,
      "objective": "What are the consequences of not addressing brain health disorders?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 9,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "b638ff59-97f7-4353-9280-5fdfd3586639",
      "evidence": "The key takeaways and key messages slides provide an overview of MindMed's goals and strengths.",
      "position": 1,
      "objective": "Why is MindMed well-positioned to address brain health disorders?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}